GlassScriptPhysician profile
Steven F Santangelo
NPI 1255314175
$13,612.65
in general payments reported to CMS, 2019-2025
38 companies · $1,600 in 2025
The $1,600 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,776 · 2020: $1,562 · 2021: $932 · 2022: $1,080 · 2023: $1,992 · 2024: $1,672 · 2025: $1,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,263.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,265.77 | 2019-2025 | Aveir, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $1,417.17 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,205.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $849.94 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $813.00 | 2019-2024 | Jardiance, Tradjenta, Glyxambi |
| Sanofi-Aventis U.S. LLC | $562.01 | 2019-2023 | |
| Lilly USA, LLC | $558.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $527.85 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $520.45 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $436.17 | 2021-2024 | |
| Amgen INC. | $399.17 | 2019-2024 | Otezla, Repatha |
| Amarin Pharma, INC. | $248.50 | 2019-2020 | |
| Astellas Pharma US INC | $239.91 | 2019-2025 | Veozah, Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $207.03 | 2019-2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $181.40 | 2019 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Santangelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.